Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?
| ISRCTN | ISRCTN57354520 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN57354520 |
| Protocol serial number | RAJ001 |
| Sponsor | University of Dundee (UK) |
| Funder | British Heart Foundation |
- Submission date
- 21/02/2006
- Registration date
- 29/03/2006
- Last edited
- 10/07/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Narasimharajapura Rajendra
Scientific
Scientific
Department of Clinical Pharmacology
Level 7
Ninewells Hospital
Dundee
DD1 9SY
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised double-blind placebo-controlled parallel group |
| Secondary study design | Randomised parallel trial |
| Study type | Participant information sheet |
| Scientific title | Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction? |
| Study objectives | Allopurinol, by inhibiting xanthine oxidase brings about a reduction in reactive oxygen species, thereby preventing adverse remodelling |
| Ethics approval(s) | Regional Ethics Committee, 07/12/2005, ref: 05/S1401/171 |
| Health condition(s) or problem(s) studied | Myocardial infarction |
| Intervention | Allopurinol versus placebo |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Allopurinol |
| Primary outcome measure(s) |
Assessment of remodelling |
| Key secondary outcome measure(s) |
Brain natriuretic peptide (BNP) |
| Completion date | 02/04/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 36 |
| Key inclusion criteria | Post myocardial infarction - days 3 to 14 |
| Key exclusion criteria | 1. Renal failure 2. Concomitant warfarin therapy 3. Allopurinol allergy |
| Date of first enrolment | 10/02/2006 |
| Date of final enrolment | 02/04/2008 |
Locations
Countries of recruitment
- United Kingdom
- Scotland
Study participating centre
Ninewells Hospital
Dundee
DD1 9SY
United Kingdom
DD1 9SY
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
10/07/2017: No publications found, verifying study status with principal investigator.
